3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
2
Oropharyngeal Neoplasms
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Plasma Cell
1
Glioma
1
Disease
1
Carcinoma, Squamous Cell
1
Interventions
lutetium Lu 177 dotatate
5
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
pembrolizumab
2
olaparib
2
fludarabine
2
cabozantinib
2
X-Rays
2
Phantoms, Imaging
2
Cyclophosphamide
2
tivozanib
1
repotrectinib
1
pazopanib
1
fludarabine phosphate
1
entrectinib
1
belinostat
1
atezolizumab
1
aldesleukin
1
Yttrium-90
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
Octreotide
1
Nivolumab
1
Introns
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Fluorodeoxyglucose F18
×
30 days
×
Clear all
No trials found.